Salarius Pharmaceuticals, Inc.
SLRX
$0.8773
-$0.0186-2.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.64M | 1.31M | 869.20K | 1.25M | 1.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.72M | 1.49M | 1.01M | 1.47M | 1.77M |
| Operating Income | -1.72M | -1.49M | -1.01M | -1.47M | -1.77M |
| Income Before Tax | -1.71M | -1.46M | -972.10K | -1.42M | -1.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.71M | -1.46M | -972.10K | -1.42M | -1.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.71M | -1.46M | -972.10K | -1.42M | -1.72M |
| EBIT | -1.72M | -1.49M | -1.01M | -1.47M | -1.77M |
| EBITDA | -1.72M | -1.49M | -1.01M | -1.47M | -1.77M |
| EPS Basic | -1.03 | -1.01 | -0.76 | -2.37 | -3.27 |
| Normalized Basic EPS | -0.64 | -0.63 | -0.47 | -1.48 | -2.04 |
| EPS Diluted | -1.03 | -1.01 | -0.76 | -2.37 | -3.27 |
| Normalized Diluted EPS | -0.64 | -0.63 | -0.47 | -1.48 | -2.04 |
| Average Basic Shares Outstanding | 1.66M | 1.44M | 1.28M | 600.40K | 524.30K |
| Average Diluted Shares Outstanding | 1.66M | 1.44M | 1.28M | 600.40K | 524.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |